ReviewAntibiotics (Basel, Switzerland)2026
A Century-Old Solution for 21st Century Challenges: Current Applications with a Focus on Biocontrol, Environmental Impacts, and Regulatory Perspectives.
Review in Antibiotics (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- From Rhizosphere to Resistance: Microbe-Plant Interactions in Eco-Smart Biocontrol.MicrobiologyOpen · 2026Review
- Chloramphenicol and tetracycline synergize with bacteriophage SeKF_13 to inactivate antimicrobial-resistantMicrobiology spectrum · 2026Article
- Genomic and phenotypic characterization of novel jumbo and small bacteriophages infectingMicrobiology spectrum · 2026Article
- Artificial Intelligence in Bacteriophage Science: A Comprehensive Narrative Review of Applications, Challenges, and Translational Opportunities.Antibiotics (Basel, Switzerland) · 2026Review
- Phenotypic and Genomic Characterization of Novel Straboviridae Bacteriophages Targeting Multidrug-ResistantMicroorganisms · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
In the face of rising antimicrobial resistance, food insecurity, and climate change, bacteriophages are gaining renewed attention as promising biological alternatives to antibiotics across human, animal, and plant health sectors. Their high specificity, self-replicating capacity, and biodegradability make them valuable tools for combating antimicrobial or pesticide resistance and promoting sustainable biocontrol. This review discusses commonly accepted selection criteria for therapeutic phages, such as avoiding temperate types and screening for undesirable genes, while acknowledging ongoing debates and exceptions in specific clinical or ecological contexts. An overview of phage-based applications within a One Health framework is provided, spanning human medicine, veterinary practice, aquaculture, food safety and crop protection. Particular attention is given to agricultural biocontrol, where several successful plant protection strategies are highlighted, illustrating the feasibility and diversity of phage-based approaches. Despite their potential, key challenges remain regarding phage stability, formulation, and persistence under environmental conditions. Emerging innovations such as encapsulation, carrier bacteria, and protective formulations aim to enhance field performance. Furthermore, this review emphasizes the need to assess the environmental safety of phage applications, particularly their impacts on natural ecosystems, microbial communities, and ecological functions. Finally, the regulatory and policy challenges that currently limit the large-scale deployment of phages, particularly in the European Union, where they remain evaluated under conventional chemical pesticide frameworks are discussed. The development of dedicated regulatory pathways, better adapted to the specificities of phages, is argued to be essential for supporting their integration into agroecological transition strategies and next-generation antimicrobial policies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.